Form D · Pharmaceuticals
Ra Pharmaceuticals, Inc.
Cambridge, MA · CIK 0001481512
Offering snapshot reported Jul 23, 2015 · SEC filing
- Reported sold
- $29.2M Offering amount: $58.5M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 10, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 23, 2015 | Initial | $29,249,996 | No comparison | 11 | SEC filing |
| Feb 24, 2010 | Initial | $10,333,082 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-244331
Source: Form D, filed Jul 23, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Bisgaard | Director |
| Kerry Black | Executive |
| James W. Broderick | Director |
| Markus Goebel | Director |
| Theodore A. Laufik | Executive |
| Jason Lettman | Director |
| Edward Mathers | Director |
| Rajeev Shah | Director |
| Lauren Silverman | Director |
| Douglas A. Treco | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
One Kendall Square Suite B14301
Cambridge, MA, 02139
Cambridge, MA, 02139